{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T16:30:07Z","timestamp":1787070607101,"version":"build-2736575974"},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:title>Abstract:<\/jats:title>\n                  <jats:p>\n                    Immunologic rejection is a significant cause of graft failure in high-risk keratoplasty, with rejection rates exceeding 70% without immunosuppressive therapy. Cyclosporine A (CsA) is emerging as a valuable adjunct to corticosteroids, the standard rejection prevention therapy. A literature review conducted in March 2024 through PubMed, Proquest, and Google Scholar utilized keywords (keratoplasty OR \u201chigh risk keratoplasty\u201d OR \u201chigh risk corneal transplantation\u201d OR \u201ccorneal transplantation\u201d) AND (cyclosporine OR ciclosporin OR ciclosporine), covering studies from 2000 to 2024. The review included three randomized controlled trials, four retrospective cohort studies, and one retrospective case\u2013control study, evaluating rejection-free graft survival rates and side effects associated with CsA therapy. Topical CsA significantly reduced rejection events compared to controls at 1 year follow-up (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 215, 17.78% vs. 32.41%, risk ratios [RR] 0.55, 95% confidence interval [CI]: 0.34\u20130.92,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.02,\n                    <jats:italic toggle=\"yes\">I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    = 31%, fixed effects), whereas systemic CsA showed no significant difference (\n                    <jats:italic toggle=\"yes\">n<\/jats:italic>\n                    = 248, 19.33% vs. 24.81%, RR 0.66, 95% CI: 0.40\u20131.08,\n                    <jats:italic toggle=\"yes\">P<\/jats:italic>\n                    = 0.10,\n                    <jats:italic toggle=\"yes\">I<\/jats:italic>\n                    <jats:sup>2<\/jats:sup>\n                    = 0%, fixed effects). No significant difference in graft survival rates was observed between the CsA and control groups. Systemic CsA was associated with systemic side effects, whereas topical CsA primarily caused ocular side effects. In summary, topical CsA significantly reduces rejection rates without substantial ocular or systemic side effects.\n                  <\/jats:p>","DOI":"10.4103\/ojo.ojo_288_24","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T19:00:11Z","timestamp":1772218811000},"page":"28-36","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Cyclosporine A as an adjuvant therapy in high-risk penetrating keratoplasty: A systematic review and meta-analysis"],"prefix":"10.4103","volume":"19","author":[{"given":"Tania","family":"Tandra","sequence":"first","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarissa","family":"Djarizal","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syska","family":"Widyawati","sequence":"additional","affiliation":[{"name":"Corneal, Cataract, and Refractive Surgery Division, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yulia","family":"Aziza","sequence":"additional","affiliation":[{"name":"Ocular Infection and Immunology Division, Faculty of Medicine, University of Indonesia - Cipto Mangunkusumo National General Hospital, Jakarta, Indonesia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,2,27]]},"reference":[{"key":"R1-20260302","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4103\/ijmr.IJMR_141_19","article-title":"Corneal transplantation in the modern era","volume":"150","author":"Singh","year":"2019","journal-title":"Indian J Med Res"},{"key":"R2-20260302","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.survophthal.2016.12.010","article-title":"Management of high-risk corneal transplantation","volume":"62","author":"Zazzo","year":"2017","journal-title":"Surv Ophthalmol"},{"key":"R3-20260302","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3844\/ajisp.2006.29.34","article-title":"Topical cyclosporine A in corneal graft rejection","volume":"2","author":"Nejabat","year":"2006","journal-title":"Am J Immunol"},{"key":"R4-20260302","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1007\/s40135-017-0119-2","article-title":"Update on the management of high-risk penetrating keratoplasty","volume":"5","author":"Jabbehdari","year":"2017","journal-title":"Curr Ophthalmol Rep"},{"key":"R5-20260302","doi-asserted-by":"crossref","first-page":"81","DOI":"10.4103\/2008-322X.200156","article-title":"Systemic immunomodulatory strategies in high-risk corneal transplantation","volume":"12","author":"Abud","year":"2017","journal-title":"J Ophthalmic Vis Res"},{"key":"R6-20260302","doi-asserted-by":"crossref","first-page":"284","DOI":"10.47830\/jinma-vol.72.6-2022-785","article-title":"Clinical and graft survival characteristics of optical penetrating keratoplasty at a tertiary care center in Indonesia: A 4-years retrospective study","volume":"72","author":"Widyawati","year":"2023","journal-title":"J Indones Med Assoc"},{"key":"R7-20260302","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10792-015-0137-8","article-title":"Systemic cyclosporine and corneal transplantation","volume":"36","author":"Ziaei","year":"2016","journal-title":"Int Ophthalmol"},{"key":"R8-20260302","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1016\/j.ophtha.2006.05.022","article-title":"Efficacy of topical cyclosporine 0.05% for prevention of cornea transplant rejection episodes","volume":"113","author":"Price","year":"2006","journal-title":"Ophthalmology"},{"key":"R9-20260302","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/S0886-3350(00)00364-3","article-title":"Effect of topical anti-inflammatory drugs on corneal and limbal wound healing","volume":"26","author":"Barba","year":"2000","journal-title":"J Cataract Refract Surg"},{"key":"R10-20260302","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1177\/11206721211023320","article-title":"Topical corticosteroids with topical cyclosporine a versus topical corticosteroids alone for immunological corneal graft rejection","volume":"32","author":"Marques","year":"2022","journal-title":"Eur J Ophthalmol"},{"key":"R11-20260302","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1136\/bjo.2009.172577","article-title":"Efficacy of topical ciclosporin a for treatment and prevention of graft rejection in corneal grafts with previous rejection episodes","volume":"94","author":"Javadi","year":"2010","journal-title":"Br J Ophthalmol"},{"key":"R12-20260302","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.survophthal.2009.02.002","article-title":"Topical ophthalmic cyclosporine: Pharmacology and clinical uses","volume":"54","author":"Donnenfeld","year":"2009","journal-title":"Surv Ophthalmol"},{"issue":"WMC 001199","key":"R13-20260302","first-page":"1","article-title":"Corneal graft rejection: a review of literature and recent advances","volume":"1","author":"Bali","year":"2010","journal-title":"WebmedCentral Ophthalmol"},{"key":"R14-20260302","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1136\/bjo.85.12.1464","article-title":"Systemic cyclosporin A in high risk penetrating keratoplasties: A case-control study","volume":"85","author":"Poon","year":"2001","journal-title":"Br J Ophthalmol"},{"key":"R15-20260302","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1097\/01.TP.0000158022.62059.F2","article-title":"Immunosuppression with cyclosporine A and mycophenolate mofetil after penetrating high-risk keratoplasty: A retrospective study","volume":"79","author":"Birnbaum","year":"2005","journal-title":"Transplantation"},{"key":"R16-20260302","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1136\/bjo.2008.143024","article-title":"Evaluation of topical ciclosporin 0.05% for prevention of rejection in high-risk corneal grafts","volume":"92","author":"Unal","year":"2008","journal-title":"Br J Ophthalmol"},{"key":"R17-20260302","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1007\/s00417-010-1388-8","article-title":"Efficacy of topical cyclosporine a 2% in prevention of graft rejection in high-risk keratoplasty: A randomized controlled trial","volume":"248","author":"Sinha","year":"2010","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"R18-20260302","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ajo.2011.01.019","article-title":"Prospective, randomized study of the efficacy of systemic cyclosporine in high-risk corneal transplantation","volume":"152","author":"Shimazaki","year":"2011","journal-title":"Am J Ophthalmol"},{"key":"R19-20260302","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0021-5155(99)00223-3","article-title":"Long-term effects of topical cyclosporine a treatment after penetrating keratoplasty","volume":"44","author":"Inoue","year":"2000","journal-title":"Jpn J Ophthalmol"},{"key":"R20-20260302","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/01.ICL.0000062460.03555.32","article-title":"Topical cyclosporine in pediatric keratoplasty","volume":"29","author":"Cosar","year":"2003","journal-title":"Eye Contact Lens"},{"key":"R21-20260302","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/S0021-5155(01)00339-2","article-title":"Long-term outcome of systemic cyclosporine treatment following penetrating keratoplasty","volume":"45","author":"Inoue","year":"2001","journal-title":"Jpn J Ophthalmol"},{"key":"R22-20260302","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1136\/bjo.86.9.988","article-title":"Systemic cyclosporin a in high failure risk, repeated corneal transplantation","volume":"86","author":"Rumelt","year":"2002","journal-title":"Br J Ophthalmol"},{"key":"R23-20260302","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1097\/ICO.0000000000002209","article-title":"Risk factors for the development of ocular hypertension after keratoplasty: A systematic review","volume":"39","author":"Liesenborghs","year":"2020","journal-title":"Cornea"},{"key":"R24-20260302","doi-asserted-by":"crossref","first-page":"70","DOI":"10.3341\/kjo.2015.29.1.70","article-title":"Successful treatment of orbital lymphangioma with intralesional bleomycin and application of continuous negative pressure","volume":"29","author":"Lee","year":"2015","journal-title":"Korean J Ophthalmol"},{"key":"R25-20260302","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1097\/TP.0000000000002938","article-title":"High-risk corneal transplantation: Recent developments and future possibilities","volume":"103","author":"Armitage","year":"2019","journal-title":"Transplantation"}],"container-title":["Oman Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_288_24","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:32:08Z","timestamp":1787067128000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/ojo.ojo_288_24"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.4103\/ojo.ojo_288_24","relation":{},"ISSN":["0974-620X","0974-7842"],"issn-type":[{"value":"0974-620X","type":"print"},{"value":"0974-7842","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"2024-09-09","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-01-15","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}